1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
AI Validation - Clinical Trials to Validate AI-Driven Drug Repurposing is sponsored by Cures Within Reach. This program supports investigator-initiated, proof-of-concept, Phase I or Phase IIA clinical trials to validate AI-driven repurposing opportunities for approved therapies in any unsolved disease. Eligible trials must include AI-generated data as part of the preclinical support.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing - Beacon for rare diseases Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing 31/07/2025 15:30 - 16:30 Online via Zoom Has an AI model identified a potential drug for your condition that’s ready to be validated in a clinical trial?
Join our upcoming webinar exploring the latest Cures Within Reach funding opportunity – hosted in partnership with REMEDi4ALL and Cures Within Reach! Artificial intelligence (AI) is increasingly seen as a powerful tool in the search for new treatments – especially through drug repurposing. By analysing large sets of data, AI can help identify existing medicines that might work for different conditions.
This is particularly valuable in rare diseases, where repurposing offers a potentially faster, more cost-effective path to finding treatment options. AI has shown promise in supporting this process, but a key question remains: Do AI-generated predictions actually work when tested in real-life clinical trials? Cures Within Reach is helping to explore this question through a new funding call.
They’re inviting letters of intent for Phase I/IIA clinical trials that will test and validate AI-based repurposing ideas , with a preference for rare disease . The aim is to build the evidence needed to validate and improve the AI models to help find treatments that work in real-world settings. You can visit https://bit.
ly/cwrrfps for more information. So what does this look like in practice, and how can patient groups take part? Join us in this webinar to find out!
Up to $100,000 in funding is available for early-stage clinical trials ( Phase I or IIA ) that test existing drugs or therapies for new uses, identified through AI models Additional funding is available to support community engagement alongside the trial Eligible trials must be based on AI-generated data that supports the repurposing idea The call is open to any unsolved disease, but there’s a strong preference for rare conditions and for using off-patent treatments What will we cover in this webinar?
A breakdown of what this funding call is about Advice from Cures Within Reach on what makes a strong application How patient groups can get involved in applications A practical example of a patient group contributing to an AI-led initiative The opportunity to ask any questions you might have to the Cures Within Reach team Clare Thibodeaux, PhD is Vice President of Scientific Affairs at Cures Within Reach, where she leads the organisation’s scientific initiatives and grant review processes.
With nearly 20 years of experience in research and philanthropy, Clare works closely with researchers, patient advocates, and industry partners to drive forward clinical trials in drug repurposing. She also serves on the Advisory Board for the CURE Drug Repurposing Collaboratory and plays a key role in developing funding calls. CJ Wright serves as the Director, Scientific Affairs at Cures Within Reach.
He joined the team in 2024 after graduating from Purdue University with his PharmD. CJ has experience at large and small pharmaceutical companies, academic health centers and regional hospitals and consulting companies.
This session is open to any patient group interested in learning more about this unique funding opportunity – including patient groups already involved in AI-driven clinical research, as well as those looking to better understand how AI can support drug repurposing. No technical AI experience is needed – the session is designed to be accessible regardless of where you are on your journey!
Join this webinar to learn more about this funding call and how your patient group can contribute to a successful application! Please note: the ticket window may take a few seconds to load. To secure your order, please ensure you complete the form in its entirety.
Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing Repeat!
How to be the best leader for your community Repeat! How to be the best leader for your community 22/10/2026 - 31/03/2027 Online via Zoom Masterclass , Online This masterclass series is for rare disease patient group leaders who want to improve their leadership skills. It will give participants the opportuni...
Repeat! How to be the best leader for your community Repeat! How to be the best leader for your community 22/10/2026 - 31/03/2027 Online via Zoom Masterclass , Online This masterclass series is for rare disease patient group leaders who want to improve their leadership skills.
It will give participants the opportuni... The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes.
Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors
According to the current listing, eligibility includes: Investigators with proof of concept, Phase I or Phase IIA clinical trials, preferably from non-profits/government, with openly accessible AI models. Confirm the full requirements in the official notice before applying.
The current listing shows up to $100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
AI Validation - Clinical Trials to Validate AI-Driven Drug Repurposing is funded by Cures Within Reach. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Clinical Repurposing for Veterans Initiative is sponsored by Cures Within Reach. This initiative focuses on finding and funding clinical repurposing trials that address unmet and high-priority medical needs of veterans and active military, including brain injuries. This is a very strong fit for a nonprofit focused on neurological conditions and veterans.
Funding Opportunities / RFPs (Cures Within Reach) is sponsored by Cures Within Reach. Cures Within Reach's mission is to improve patient quality and length of life by leveraging the speed, safety and cost-effectiveness of testing already approved therapies for new indications that serve philanthropic and/or commercial uses, driving more treatments to more patient…
Cures Within Reach funds investigator-initiated, proof-of-concept Phase I or Phase IIA clinical trials that validate artificial intelligence (AI)-driven drug repurposing opportunities in any unsolved disease, where the therapies flagged by AI models are already approved. AI-generated data must support the trial's preclinical foundation. There is a preference for rare diseases, off-patent drugs and biologics, and openly accessible or nonprofit/government-developed AI models. Applications are submitted through ProposalCentral.
On July 30, 2026, five food and farming nonprofits sued USDA in the Western District of Washington over grant terms and conditions that restrict what grantees may say and do — including with money that never came from the federal government. Twenty states and DC filed a parallel challenge in March. Here is what the conditions actually say and what recipients should do before their next award letter arrives.
Read articleHRSA-26-078 splits $9.1 million among roughly 10 Public Health Training Centers, with awards up to $910,000 and applications due July 17, 2026. Eligibility runs to accredited schools of public health and other nonprofit training institutions. Here's why the winning applications are the ones that can prove an existing, mapped relationship with state and local health departments — not the ones promising the slickest coursework.
Read articleThe Department of Education's May 19 final rule activates Workforce Pell on July 1, 2026, opening federal aid to short-term training programs as brief as 8 weeks. Governors and state workforce boards — not accreditors — pick the eligible industries, and only programs that pass earnings-vs-cost gates make the list.
Read article